Kristen Fortney, BioAge Labs CEO
September 26, 2024 03:11 AM EDT
Financing
Startups

Next-gen obe­si­ty biotech BioAge Labs to raise $198M in IPO

Kyle LaHucik

Senior Reporter

A Cal­i­for­nia biotech that be­gan as an an­ti-ag­ing com­pa­ny, then li­censed an Am­gen heart fail­ure drug for $1 mil­lion up­front and re­pur­posed it as a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times